Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Drugs - Real World Outcomes
|
August 29, 2019
Development and Application of a Measurement Framework to Evaluate Safe, Effective and Efficient Medication Use Among Older Adults
Ami Vyas, Emily Patry, Norma Owens, et al.
Clinical Transplantation
|
November 3, 2018
Outcomes in human immunodeficiency virus-infected recipients of heart transplants
Chao Chen, Xuerong Wen, Anju Yadav, et al.
JAMA Network Open
|
April 13, 2021
Association of Gestational Opioid Exposure and Risk of Major and Minor Congenital Malformations
Xuerong Wen, Nicholas Belviso, Emily Murray, et al.
Pharmacotherapy
|
May 1, 2021
Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study
Nicholas Belviso, Herbert D Aronow, Richard Wyss, et al.
Rhode Island Medical Journal (2013)
|
August 11, 2019
Prescription Opioid Use among Pregnant Women Enrolled in Rhode Island Medicaid
Xuerong Wen, Nicholas Belviso, Rebecca Lebeau, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program
Marco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Drug Safety
|
June 8, 2021
Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study
Xuerong Wen, Oluwadolapo D Lawal, Nicholas Belviso, et al.
Journal of Medical Economics
|
June 21, 2026
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis
Jeffrey Kaplan, Dana Beenstock, Martin Belkin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
January 13, 2022
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
Carrie M Hersh, Arman Altincatal, Nicholas Belviso, et al.
Multiple Sclerosis and Related Disorders
|
June 14, 2022
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab
Jacqueline A Nicholas, Mark Gudesblatt, Meghan Garabedian, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Drugs - Real World Outcomes
|
August 29, 2019
Development and Application of a Measurement Framework to Evaluate Safe, Effective and Efficient Medication Use Among Older Adults
Ami Vyas, Emily Patry, Norma Owens, et al.
Clinical Transplantation
|
November 3, 2018
Outcomes in human immunodeficiency virus-infected recipients of heart transplants
Chao Chen, Xuerong Wen, Anju Yadav, et al.
JAMA Network Open
|
April 13, 2021
Association of Gestational Opioid Exposure and Risk of Major and Minor Congenital Malformations
Xuerong Wen, Nicholas Belviso, Emily Murray, et al.
Pharmacotherapy
|
May 1, 2021
Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study
Nicholas Belviso, Herbert D Aronow, Richard Wyss, et al.
Rhode Island Medical Journal (2013)
|
August 11, 2019
Prescription Opioid Use among Pregnant Women Enrolled in Rhode Island Medicaid
Xuerong Wen, Nicholas Belviso, Rebecca Lebeau, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program
Marco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Drug Safety
|
June 8, 2021
Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study
Xuerong Wen, Oluwadolapo D Lawal, Nicholas Belviso, et al.
Journal of Medical Economics
|
June 21, 2026
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis
Jeffrey Kaplan, Dana Beenstock, Martin Belkin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
January 13, 2022
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
Carrie M Hersh, Arman Altincatal, Nicholas Belviso, et al.
Multiple Sclerosis and Related Disorders
|
June 14, 2022
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab
Jacqueline A Nicholas, Mark Gudesblatt, Meghan Garabedian, et al.
Page
of 3